Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Wilson Bernales

Adult Medicine Casper, WY Medical Doctor

NPI 1508824467 CMS profile 576593

428 S Durbin St, Suite 104, Casper, WY 82601

Open in the dashboard

General payments

$23,306

310 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Wilson Bernales of Casper, WY is reported in the CMS Open Payments database as having received $23,306 across 310 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 98th percentile of Adult Medicine profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $3,604 49
2024 General $4,627 50
2023 General $3,300 31
2022 General $1,122 10
2021 General $5,053 75
2020 General $1,180 39
2019 General $4,419 56

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Wilson Bernales
  • Adult Medicine median
  • Middle half of Adult Medicine
  • National median

In program year 2025, general payments to Wilson Bernales were reported at $3,604. Among 691 Adult Medicine profiles paid that year, the median was $151 and the middle half received between $51 and $528.

Show as a table
Year Wilson Bernales Adult Medicine median Middle half National median
2019 $4,419 $140 $41–$517 $163
2020 $1,180 $107 $25–$378 $114
2021 $5,053 $136 $32–$529 $132
2022 $1,122 $138 $39–$492 $149
2023 $3,300 $155 $46–$483 $160
2024 $4,627 $153 $46–$554 $164
2025 $3,604 $151 $51–$528 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. AstraZeneca Pharmaceuticals LP $2,687 29 payments
  2. AbbVie, Inc. $1,889 16 payments
  3. GlaxoSmithKline, LLC. $1,655 31 payments
  4. Biohaven Pharmaceuticals, Inc. $1,438 4 payments
  5. Grifols USA, LLC $1,225 27 payments
  6. United Therapeutics Corporation $1,219 12 payments
  7. Takeda Pharmaceuticals U.S.A., Inc. $1,063 35 payments
  8. Gilead Sciences, Inc. $948 9 payments
  9. Abbott Laboratories $827 7 payments
  10. Amgen Inc. $822 9 payments
  11. Other $9,534 131 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $22,052 307 payments
  2. Consulting Fee $1,200 1 payment
  3. Education $55 2 payments
Products named General payments · program years 2019–2025
  1. NURTEC ODT $1,438 4 payments
  2. GLASSIA $1,063 35 payments
  3. Prolastin-C Liquid $940 25 payments
  4. QULIPTA $907 7 payments
  5. UBRELVY $884 7 payments
  6. FARXIGA $693 8 payments
  7. FreeStyle Libre 3 $641 5 payments
  8. VRAYLAR $582 6 payments
  9. FASENRA $495 5 payments
  10. TYVASO $486 5 payments
  11. Other $15,211 211 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Records

310 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record